Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia
Clinical trial NCT05225831 · UNKNOWN
Trial details
- NCT number
- NCT05225831
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
- Status
- UNKNOWN
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-15
- Primary completion
- 2023-08-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.